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Abstract
Purpose: Despite advances in the treatment of acute lymphoblastic leukaemia (A.L.L.), the outcome for children living 
in the developing countries is still poor. This is in large part due to high treatment-related mortality (TRM). This study was 
carried out to review the data and analyze the factors resulting in high TRM during remission induction chemotherapy.
Methods: Data for children treated at our centre during the calendar year 2007 were retrospectively analysed. 
Standard four-drug induction chemotherapy was used without risk stratification. Bone marrow evaluation was carried 
out at days 8 and 28. Cerebrospinal fluid analysis was carried out on day 1 and with each subsequent intrathecal 
chemotherapy injection. Modern supportive care facilities including antibiotics, nutritional support and intensive care 
unit were available.
Results: Eighty-one children were eligible for analysis. Median age was 5 years (range 2–16), 72% were male with 
M:F ratio of 2.5:1. Seventy-five (92%) children had precursor B-cell A.L.L. Only 2 children had central nervous 
system leukaemia at presentation. Median presenting white blood cell count was 8.83 (range: 1–446). Severe 
malnutrition (weight <5th centile for age) was seen in 42% of children. Median symptom duration was 6 (range 1–30) 
weeks at the time of presentation. Induction mortality was 25%. Induction mortality was 25.6% (n = 21). Twenty 
were related to infections, while more than half (52%) occurred as a result of an outbreak of Acinetobacter infection. 
Severe malnutrition and Acinetobacter infection (due to an outbreak in our unit during the study period) were highly 
predictive of TRM during remission induction chemotherapy.
Conclusions: Infection control measures, health education and reduction in treatment intensity may improve survival 
for children with A.L.L. in Pakistani population.
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Acute lymphoblastic leukaemia (A.L.L.) is an eminently 
curable cancer of children, and an increasing number of 
groups are reporting long-term survival in excess of 80%. 
This success is attributable to advances in understanding 
of the disease biology and leukaemia cytogenetics, as 
well as advances in supportive care, in addition to the 
refinement of treatment such as minimal residual disease 
(MRD) analysis.[1-3] The same degree of success, however, 
has not been duplicated in resource-poor countries. This 
is thought to be related to a number of factors, including 
delayed presentation, lack of resources for individual 
families and low prioritisation of cancer in some health 
systems. Poverty predisposes children to malnourishment 
which may contribute to the severity of infections when 
exposed to anticancer chemotherapy. The poor outcome 
is also attributable to delay in diagnosis, interruptions in 
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treatment due to its toxicity and poor compliance with 
treatment.[4,5] Lack of effective supportive care results in 
poor salvage rates when children experience treatment-
related toxicity. Non-availability of sophisticated markers 
such as cytogenetic analysis and MRD analysis may also 
contribute at least to some extent to poor outcomes as these 
techniques can be useful in identifying children at high 
risk of relapse with standard treatment on the one hand and 
those requiring less intense therapy on the other.[6] In most 
recent series in the Western literature, reported induction 
mortality is <1%.[7] There are very few published studies 
reporting outcomes of A.L.L. from Pakistan.[8,9] Recently 
published series from India have reported induction 
mortality between 2% and 25%.[10-13]
Shaukat Khanum Memorial Cancer Hospital and Research 
Centre is a philanthropically supported, modern cancer 
centre in Lahore, Pakistan. After an initial clinical triage 
process, patients are registered and treatment is provided 
irrespective of their ability to pay for it. A number of 
patients travel long distances for treatment at this centre. 
Approximately 350–400 new children with different 
paediatric cancers are registered for treatment every year 
at this centre. Outcome analysis for A.L.L. is beyond the 
scope of this study. The objective of this study was to assess 
the toxicity of the regimen used in the study population and 
analyse factors resulting in early treatment-related death.
Methods
Data were analysed retrospectively for children treated 
at our centre for A.L.L. during the calendar year 2007. 
Patients who had received prior treatment and those who 
presented in relapse were excluded from analysis. SPSS 
statistical software version 16 was used for statistical 
analysis. Diagnosis was confirmed with bone marrow or 
peripheral blood immunophenotyping of leukaemic blasts 
by flow cytometery. Further bone marrow examinations 
were undertaken on day 8 for all and day 28 for patients 
who had either M2, M3 or hypocellular marrows on day 
8. Cerebrospinal fluid (CSF) was obtained at the time of 
diagnosis and disease was categorised according to the 
accepted groups of central nervous system (CNS) 1, 2 
and 3 status. Baseline cardiac left ventricular function 
was estimated by multigated acquisition scan before 
the first dose of daunorubicin. Baseline complete blood 
count and biochemical profile including liver function 
tests, coagulation screening and serological screening for 
hepatitis B and C were performed at the time of diagnosis. 
All patients were admitted at the time of diagnosis. 
Induction chemotherapy was started after aggressive 
intravenous hydration for 24 h once the diagnosis of 
A.L.L. was established as above.
Chemotherapy
All patients received induction chemotherapy with 
intravenous vincristine (1.5 mg/m2/dose on days 2, 9, 16, 
23 and 30), intravenous daunorubicin (25 mg/m2/dose 
on days 2, 9, 16 and 23); intramuscular l-asparaginase 
(Escherichia coli Asparaginase 6000 international 
Units/m2/dose on days 2, 4, 6, 18, 10, 12, 14, 16, 18, 20, 22, 
24 and 26) and dexamethasone(6 mg/m2/day in two divided 
doses on days 1 through 28 followed by taper over 1 week). 
Intrathecal methotrexate was given (age-dependant dose) 
on days 1, 8 and 28 for CNS-negative patients and weekly 
for CNS-positive ones. Schedule is shown in Figure 1.
Supportive care
Institutional guidelines were followed for treating febrile 
neutropenia. These included broad-spectrum antibiotics, 
usually an antipseudomonal penicillin alongside an 
aminoglycoside as the first-line therapy and carbapenem 
as the second-line antibiotic therapy. Patient with central 
venous lines and those clinically suspected to have Gram-
positive infections also received a glycopeptides (usually 
teicoplanin). Antifungal cover was added for fever 
unresponsive by 96 h. Antibiotic therapy was tailored for 
culture-proven infections according to the sensitivity of 
the organism. Supportive specialist advice for infectious 
diseases, gastroenterology and pulmonology was 
readily available by the on-site adult faculty. Neurology, 
nephrology and cardiology support was provided by 
visiting members of the faculty. Critically ill patients were 
nursed in our on-site intensive care unit where inotropic, 
ventilator and other interventional support was available. 
Product support was provided by the on-site blood bank 
and all blood products were screened for Hepatitis B and 
C and HIV.
Results
There were 81 evaluable patients enrolled for treatment 
during the study period. Median age was 5 years (range 
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2–16). Male-to-female ratio was 2.5:1. Seventy-five (92%) 
children had precursor B cell.
A.L.L., and the remaining 6 had precursor T-cell 
disease. Seventy-three (91%) children had CNS negative 
leukaemia, while only 2 had leukaemic blast cells in their 
initial CSF. Median presenting white blood cell count 
was 8.83 (range 1–446). Sixty-seven (82%) children 
fell in NCI standard-risk group. Severe malnutrition 
(weight<5th centile for age) was seen in 42% of children. 
However, the median plasma albumin concentration was 
4.01 (range 2.53–4.75). Median symptom duration was 
6 (range 1–30) weeks at the time of presentation.
Median time to initiation of treatment (days after 
registration at the hospital) was 14 (3–152) days. Patient 
characteristics are summarised in Table 1.
Response to treatment
More than half (54%) of children showed a rapid early 
response to treatment based on bone marrow morphology 
Table 2. Fourteen (17.3%) had M2 and 16 (19.8%) had M3 
marrow on day 8. By day 28, however, all the surviving 
children had M1 marrow (<5% blasts).
Toxicity
Significant toxicities were seen in majority of children. 
These included Grade 3 or 4 haematological (88%), 
infection-related (75%), gastrointestinal (44%), pulmonary 
(21%), haemorrhage (13%), liver (12%) and neurological 
(7%) toxicities.
Grade 3 and 4 haematological toxicities included 
prolonged neutropenia, thrombocytopenia and anaemia. 
Infection-related toxicities included febrile neutropenia 
with clinical or culture-proven infections with (Grade 4) or 
without (Grade 3) evidence of septic shock. These included 
bacterial, fungal and viral infections. Gastrointestinal 
toxicities included severe mucositis, esophagitis, 
diarrhoea, colitis and ileus. Pulmonary toxicities 
included X-ray-proven pneumonia, oxygen requirement 
and mechanical ventilation. Haemorrhagic toxicities 
in our patients included severe post-surgical bleeding, 
gastrointestinal haemorrhage and CNS bleeding. Liver 
Figure 1: Treatment schema for remission induction chemotheraphy
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toxicities included liver failure and CNS toxicities 
manifested in the form of convulsions. These data are 
summarised in Table 3.
Mortality
There were 21 deaths in the study population during 
remission induction chemotherapy or soon thereafter 
(before the start of consolidation). Median time 
to death was 20 days (range 9–41). Twenty of the 
21 deaths were infection related (Gram-negative 
sepsis 15; Gram-positive sepsis 2; fungal infection 2 
and pneumonia 1). The remaining one death was due 
to an intracranial bleed. These findings are summarised 
in Table 4 and 5.
Nineteen of the 20 infection-related deaths had culture-
proven infections. A total of 41 microorganisms were 
isolated (23 were Gram-negative, 12 Gram-positive 
bacteria while the remaining 6 were fungi). Five patients 
had more than one positive culture while 14 patients 










Table 2: Bone marrow response at days 8 and 28




In evaluable 5 ( 6.2)
Day 28 bone marrow**
M1 45 (100)
M status refers to percentage of blasts on morphological 
microscopic examination of bone marrow where M1 means blast 
count less than 5%, M2 5–25% and M3 more than 25% . *Two 
patients died before day 8 bone marrow examination was carried 
out. **Day 28 bone marrow examination was carried out for pa‑
tients who were not in remission on day 8. ***In 15 patients, bone 
marrow examination was carried out on day 28 despite having M1 
marrow on day 8 to confirm continuing remission. All patients had 
M1 marrow on day 28
Table 1: Patient characteristics (n=81)
Characteristics n (%) Additional information Median Range
Gender
Male 58 (71.6)
Female 23 (28.4) Symptom duration (days) 42 7–210
Age (years) 2–16 (Median: 5) Time to treatment (days) 14 3–152
NCI risk group WBC (x109/L) 8.83 1–442
Standard risk 67 (82.7) Albumin (mg/dL) 4.01 2.53–4.75
High risk 14 (17.3)
Lineage
Precursor B‑cell 75 (92.6)
Precursor T‑cell 6 (7.4)
Nutritional status
Weight <5th centile 34 (42)
Weight >5th centile 47 (58)
CSF
CNS1 (negative) 73 (90.1)
CNS2 (trauma) 5 (6.2)
CNS3 (positive) 2 (2.5)
CSF: Cerebrospinal fluid, CNS: Central nervous system, WBC: White blood cell
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The most common organism isolated during the study 
period was Acinetobacter species (in 12 patients). All 
of the isolated Acinetobacter were multidrug resistant. 
This organism was also associated with a very high 
mortality (91%). Median time from the isolation of first 
Acinetobacter in body fluid cultures to death was 1 day 
(range 0–23).
Details of these organisms are given in Table 6 and 
Figures 1 and 2.
Five (35.7%) of the children in the National Cancer 
Institute (NCI) high-risk group died compared to 
16 (23.9%) in NCI standard-risk group. However, these 
differences were not statistically significant.
Nutritional status
Thirty-four (42%) of children were severely malnourished 
i.e., weight less than 5th centile for age according to the 
Tanner-Whitehouse growth charts. Median serum albumin 
concentration was 4.01 g/dL. 16 (47%) of severely 
malnourished children died compared to 5 (8.6%) who 
were not severely malnourished. Severe malnourishment 
was significantly correlated to the risk of induction 
Table 4: Cause of death (n=21)
Cause of death n (%)
Gram‑negative sepsis 15 (71.4)
Gram‑positive sepsis 2 (9.5)
Fungal infection 2 (9.5)
Pneumonia 1 (4.8)
Intracranial bleed 1 (4.8)
Table 5: Death analysis (n=21; 25%)
Factors n (%) Significance
NCI risk group
NCI standard risk 16 (23.8) P=0.364
NCI high risk 5 (35.7)
Morphology
Precursor B 19 (25.3) P=0.672
Precursor T 2 (33.3)
Nutritional status
Not malnourished 5 (17.8) P=0.008
Malnourished 16 (30.1)
Infection
Acinetobacter 11 (91) P=0.000
No acinetobacter 10 (14)
Time to death: 9‑41 days (median 21 days)
Table 6: Characteristics of Acinetobacter species 




Tracheal aspirate 4 (25)
Sensitivity pattern
Multidrug resistant 12 (100)
Sensitive 0
Blood counts
Neutrophils <1.0 7 (58)





ICU: Intensive care unit
Figure 2: (a) Microorganisms isolated during induction (n=90). 
(b) Microorganisms isolated from patients who later died (n=41)
a
b
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mortality (P = 0.008). However, a lower serum albumin 
was not correlated to mortality in our series.
Discussion
There are limited data on disease characteristics and outcomes 
of A.L.L. for Pakistani children.[8,9] To our knowledge, 
this is the first study from Pakistan reporting treatment-
related mortality (TRM) for ALL induction therapy. Aziz 
et al. analysed the prognostic implication of presentation 
characteristics and outcome analysis using a modified 
BFM protocol in 2002. Reported induction mortality was 
in keeping with other published data from this part of the 
world. Their sample size was small, making it difficult to 
draw any definitive conclusions.[8] Khalid et al. have recently 
described a single-centre experience over 18 years using 
six different treatment protocols. Their starting sample size 
was 96. However, 52% were excluded for various reasons, 
leaving a small sample. Some of the traditional prognostic 
factors were confirmed while others were not found to be of 
any significance. They do not describe TRM.[9]
In the absence of consensus local guidelines and 
prospective cooperative trials, treatment of A.L.L. in 
Pakistan and indeed in many other developing countries of 
the world has historically been modelled on the templates 
of recognised international protocols. A standard four-drug 
chemotherapy regimen was used for all children during 
the remission induction phase without risk stratification. 
Template of the intermediate-risk arm of the UKALL 2003 
study was followed, which was the current (at the time) 
CCLG UK protocol.
The results of our study show that there was a much higher 
than expected mortality (25.9%) in this population. This 
was primarily related to an outbreak of Acinetobacter 
infection during the study period. This organism, while 
of low virulence in the immunocompetent, is associated 
with a high mortality in the immunocompromised 
and seriously ill patients.[14] Our study population, 
which was at increased risk of mortality due to severe 
malnourishment and exposure to myelosuppressive 
chemotherapy, contracting Acinetobacter was highly 
predictive of mortality.
Successful implementation of infection control measures 
has since brought the incidence and resulting in 
high mortality under control (hospital data, personal 
communication). If all the Acinetobacter cases are 
excluded from the analysis, induction mortality in the 
remaining group would be 11% that is more in keeping 
with other studies from the region.
Poor nutritional reserves, poor personal hygiene and 
overcrowded living conditions all contribute to poor 
chemotherapy tolerance, severe immune suppression and 
early death. Displacement from hometown has a dual 
impact on family incomes (i.e. losing primary income 
and incurring additional expense by staying away from 
home). Our results show significantly higher induction 
mortality in severely malnourished group. Others have 
also reported high TRM in malnourished children and in 
children belonging to poor socioeconomic and educational 
backgrounds.[5,15-17]
For several years, the poor outcome of childhood A.L.L. 
in this part of the world has been assumed to be at least 
partly related to adverse cytogenetic changes, hence the 
tendency of treatment with intensive regimens without 
stratification. Siraj et al. reported a higher incidence of 
adverse cytogenetics and a lower incidence of favourable 
translocation in Indian children with A.L.L. compared to 
Europeans and Americans. Faiz and Qazi also reported 
a less than expected favourable translocation t (12; 
21) in Pakistani population.[18,19] However, even the 
highest estimates place the adverse cytogenetics group 
around 7–8%, which would still mean that over 90% of 
children could possibly be stratified to receive a lower 
intensity treatment. The importance of risk stratification 
is thus highlighted based on conventional, molecular and 
cytogenetic criteria to avoid over or under treatment.
Glucocorticoids are an essential part of A.L.L. treatment. 
Through the past many decades, prednisolone has been 
used by all major cooperative groups. Much is known 
about its efficacy and toxicity. Over the recent years , 
studies have shown that dexamethasone to be superior due 
to a relatively increased CNS penetration and reduction in 
the risk of CNS and bone marrow relapse. Mitchell et al. 
demonstrated that risk of CNS and non-CNS relapse in 
the group randomised to dexamethasone was half that of 
the prednisolone group in a randomised fashion. However, 
it is also known that dexamethasone is associated with 
increased risk of infections and other organ-system 
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toxicities.[20] Increased mortality individually as well as 
in combination with daunorubicin has been reported.[21,22] 
Inclusion of dexamethasone in the four-drug regimen 
may have had a compound contributory effect to the high 
toxicity profile of this regimen in our population.
We conclude that strict infection control measures are 
required to reduce induction mortality for A.L.L. Health 
education regarding improving hygiene and reducing 
overcrowding is paramount to reduce the infections and 
related mortality. Toxicity of treatment and induction 
mortality can be brought down by low-intensity regimen 
to low- and standard-risk patients. These changes have 
already been introduced and will need to be examined in 
future studies.
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